Decoupling between SARS-CoV-2 transmissibility and population mobility associated with increasing immunity from vaccination and infection in South America.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 04 2022
27 04 2022
Historique:
received:
29
09
2021
accepted:
14
04
2022
entrez:
28
4
2022
pubmed:
29
4
2022
medline:
30
4
2022
Statut:
epublish
Résumé
All South American countries from the Southern cone (Argentina, Brazil, Chile, Paraguay and Uruguay) experienced severe COVID-19 epidemic waves during early 2021 driven by the expansion of variants Gamma and Lambda, however, there was an improvement in different epidemic indicators since June 2021. To investigate the impact of national vaccination programs and natural infection on viral transmission in those South American countries, we analyzed the coupling between population mobility and the viral effective reproduction number [Formula: see text]. Our analyses reveal that population mobility was highly correlated with viral [Formula: see text] from January to May 2021 in all countries analyzed; but a clear decoupling occurred since May-June 2021, when the rate of viral spread started to be lower than expected from the levels of social interactions. These findings support that populations from the South American Southern cone probably achieved the conditional herd immunity threshold to contain the spread of regional SARS-CoV-2 variants circulating at that time.
Identifiants
pubmed: 35478213
doi: 10.1038/s41598-022-10896-4
pii: 10.1038/s41598-022-10896-4
pmc: PMC9044384
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6874Informations de copyright
© 2022. The Author(s).
Références
Rev Chilena Infectol. 2022 Jun;39(3):238-247
pubmed: 36156684
Nat Med. 2021 Jun;27(6):1055-1061
pubmed: 33875890
Sci Immunol. 2022 Feb 18;7(68):eabn8014
pubmed: 35076258
JAMA. 2021 Dec 28;326(24):2524-2526
pubmed: 34724529
Ann Intern Med. 2021 Nov;174(11):1586-1591
pubmed: 34516275
Emerg Infect Dis. 2021 Nov;27(11):2957-2960
pubmed: 34437831
Virus Evol. 2022 Mar 17;8(1):veac002
pubmed: 35310621
Lancet Reg Health Am. 2022 Feb;6:100154
pubmed: 34957437
Epidemiol Infect. 2020 Nov 13;148:e284
pubmed: 33183366
Science. 2020 May 1;368(6490):493-497
pubmed: 32213647
Nature. 2021 Jul;595(7867):426-431
pubmed: 34126625
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Nat Med. 2021 Aug;27(8):1367-1369
pubmed: 34113015
N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
Nat Med. 2021 Aug;27(8):1370-1378
pubmed: 34108716
Science. 2020 Aug 14;369(6505):846-849
pubmed: 32576668
Nature. 2021 Mar;591(7851):520-522
pubmed: 33737753
medRxiv. 2021 Dec 24;:
pubmed: 34988559
Lancet Infect Dis. 2022 Jan;22(1):56-63
pubmed: 34509185
Nat Commun. 2021 Nov 4;12(1):6379
pubmed: 34737312
JAMA. 2021 Jul 6;326(1):35-45
pubmed: 34037666
Nat Commun. 2021 Feb 17;12(1):1090
pubmed: 33597546
Lancet Infect Dis. 2020 Nov;20(11):1247-1254
pubmed: 32621869
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Lancet. 2020 Nov 21;396(10263):1614-1616
pubmed: 33159850
Nat Med. 2021 Dec;27(12):2127-2135
pubmed: 34650248
PLoS One. 2021 Jul 29;16(7):e0255412
pubmed: 34324603
Hist Philos Life Sci. 2021 Feb 10;43(1):18
pubmed: 33566215
Nat Commun. 2021 Mar 8;12(1):1501
pubmed: 33686075
BMJ. 2021 Nov 24;375:e067873
pubmed: 34819275
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
N Engl J Med. 2021 Sep 2;385(10):875-884
pubmed: 34233097
J Theor Biol. 2022 May 7;540:111063
pubmed: 35189135
JAMA. 2020 Nov 24;324(20):2095-2096
pubmed: 33074293
Nat Commun. 2020 Dec 3;11(1):6189
pubmed: 33273462
Clin Microbiol Infect. 2022 Jun;28(6):852-858
pubmed: 35182757